Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV,PG,RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
0.5 ml |
Concentrate |
RUO |
501-4562 |
-
|
Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV, PG, RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
Zytomed Systems |
SP156 |
1 ml |
Concentrate |
RUO |
501-4564 |
-
|
Host |
Rabbit |
Klon |
EP261 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3058A |
-
|
Host |
Rabbit |
Klon |
EP261 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasma and nucleus |
Arginase-1
|
Biocare Medical |
EP261 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3058B |
-
|
Host |
Rabbit |
Klon |
EP261 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic and nuclear |
Arginase-1
|
Biocare Medical |
EP261 |
6 ml |
Ready-to-use |
CE/IVD |
API3058AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
keine |
Positivkontrolle |
Herz |
Verdünnung |
5 µg/mL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to a portion of the amino acid sequence between 300-450 of human ATG4-KLH conjugated |
ATG4B
|
Zytomed Systems |
polyclonal |
50 µg |
Purified |
RUO |
601-0367 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
0.1 ml |
concentrate |
CE/IVD |
ACI3251A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
1 ml |
concentrate |
CE/IVD |
ACI3251C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3251G7 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3251AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
ATRX
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3251G |
-
|
Host |
Mouse |
Klon |
D-5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA Puffer, pH 8,0 |
Positivkontrolle |
Pancreas |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2a kappa |
Verdünnung |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Lokalisation |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
1 ml |
Concentrate |
CE/IVD |
MOB600 |
-
|
Host |
Mouse |
Klon |
D-5 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA Puffer, pH 8,0 |
Positivkontrolle |
Pancreas |
Verdünnung |
--- |
Isotyp |
Mouse IgG2a kappa |
Verdünnung |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Lokalisation |
nuclear |
ATRX
|
Diagnostic Biosystems |
D-5 |
6 ml |
ready-to-use |
CE/IVD |
PDM600 |
-
|
Host |
Mouse |
Klon |
35C1 |
Format |
Purified |
Methode |
WB, IP, IF |
Isotyp |
Mouse IgG2b |
Verdünnung |
Recombinant Aurora-A |
Aurora A Kinase
|
Zytomed Systems |
35C1 |
100 µg |
Purified |
RUO |
601-0320 |
-
|
Host |
Mouse |
Klon |
2213 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Highly pure beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems |
2213 |
1 mg |
Purified |
RUO |
602-0004 |
-
|
Host |
Mouse |
Klon |
B2M-01 |
Format |
Purified |
Methode |
EL, FL |
Isotyp |
Mouse IgG2a |
Verdünnung |
Beta-2-microglobulin from human urine |
b2-Microglobulin
|
Zytomed Systems |
B2M-01 |
250 µg |
Purified |
RUO |
602-0005 |
-
|
Host |
Mouse |
Klon |
TLD-3H12B |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems |
TLD-3H12B |
250 µg |
Purified |
RUO |
602-0007 |
-
|
Host |
Mouse |
Klon |
TLD-3H12B |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat microglial cells |
b2-Microglobulin
|
Zytomed Systems |
TLD-3H12B |
100 µg |
Purified |
RUO |
602-0008 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI3247A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
ACI3247B |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3247G7 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3247AA |
-
|
Host |
Mouse |
Klon |
C-4 |
Format |
ready-to-use |
Methode |
FFPE |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
--- |
Isotyp |
IgG1, kappa |
Verdünnung |
Synthetic peptide against 430-729 of human BAP1 |
Lokalisation |
nuclear and cytoplasmic |
BAP1 (BRCA1-Associated Protein 1)
|
Diagnostic Biosystems |
C-4 |
6 ml |
ready-to-use |
CE/IVD |
PDM595 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from internal region of human BAX protein |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
polyclonal |
7 ml |
Ready-to-use |
RUO |
502-17991 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from internal region of human BAX protein |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
polyclonal |
1 ml |
Concentrate |
RUO |
502-17994 |
-
|
Host |
Rabbit |
Klon |
SP47 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human Bak. |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
SP47 |
0.5 ml |
Concentrate |
RUO |
502-3472 |
-
|
Host |
Rabbit |
Klon |
SP47 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human Bak. |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
Zytomed Systems |
SP47 |
1 ml |
Concentrate |
RUO |
502-3474 |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
Biocare Medical |
Cu-18 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3241A |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
Biocare Medical |
Cu-18 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3241B |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
Biocare Medical |
Cu-18 |
6 ml |
Ready-to-use |
CE/IVD |
API3241AA |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
1 ml |
Concentrate |
CE/IVD |
Z2141ML |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
7 ml |
Ready-to-use |
CE/IVD |
Z2141MP |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
0.5 ml |
Concentrate |
CE/IVD |
Z2141MS |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
0.1 ml |
Concentrate |
CE/IVD |
Z2141MT |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
1.0 ml |
Concentrate |
CE/IVD |
Z2022ML |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
7 ml |
Ready-to-use |
CE/IVD |
Z2022MP |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
0.5 ml |
Concentrate |
CE/IVD |
Z2022MS |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
0.1 ml |
Concentrate |
CE/IVD |
Z2022MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
1.0 ml |
Concentrate |
CE/IVD |
Z2343ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
7 ml |
Ready-to-use |
CE/IVD |
Z2343MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
0.5 ml |
Concentrate |
CE/IVD |
Z2343MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
0.1 ml |
Concentrate |
CE/IVD |
Z2343MT |
-
|
Host |
Mouse |
Klon |
100 |
Format |
Purified |
Methode |
F, WB, P, IP, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:20 - 1:40 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide, amino acids 41-54 of the Bcl-2 protein |
BCL2
|
Zytomed Systems |
100 |
100 µg |
Purified |
RUO |
602-0045 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
1 ml |
Concentrate |
CE/IVD |
MOB005 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
0.1 ml |
Concentrate |
CE/IVD |
MOB005-01 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
0.5 ml |
Concentrate |
CE/IVD |
MOB005-05 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
1 ml |
Concentrate |
CE/IVD |
MOB130 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB130-01 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB130-05 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
6 ml |
Ready-to-use |
CE/IVD |
PDM016 |
-
|